News & Comment

Filter By:

  • The US Supreme Court’s ruling to overturn Roe v. Wade will affect patients with cancer and cancer care providers across the United States. In this time of uncertainty, it is imperative to protect health rights and evidence-based care.

  • The advent of immunotherapy has revolutionized the cancer field, but it is not without its challenges. In this issue, we launch our Series on Cancer Immunotherapy presenting commissioned Reviews and opinion pieces on the latest advances and efforts to expand the palette of immunotherapies and their clinical translation.

  • As guidelines, therapies and literature on cancer variants expand, the lack of consensus variant interpretations impedes clinical applications. CIViC is a public-domain, crowd-sourced and adaptable knowledgebase of evidence for the clinical interpretation of variants in cancer, designed to reduce barriers to knowledge sharing and alleviate the variant-interpretation bottleneck.

    • Kilannin Krysiak
    • Arpad M. Danos
    • Malachi Griffith
  • Nature Cancer and the Nature journals are raising the standards on reporting on sex and gender in research. Starting this June, authors will be prompted to provide details on how sex and gender were considered in study design.

  • The advent of EGFR inhibitors has been a game changer in clinical oncology. However, differing sensitivity to different mutations, resistance and adverse effects continue to impede decisive treatment of mutant EGFR–driven cancers, which highlights the need for advanced and innovative EGFR-targeting approaches.

  • A deeper understanding of the specific tumor context and microenvironment, the underlying tumor immunology, and barriers to effective treatment, including therapy resistance and adverse effects, is essential to the development of improved immunotherapy modalities and regimens.

  • A deeper understanding of the molecular and cellular underpinnings of metastatic disease and a renewed focus on metastasis-targeting therapeutic approaches raise hopes for improved clinical translation.

  • Rapid progress in the molecular characterization of cancer genomes has been enabled by technology and computational analysis, and large databases now exist. Novel cancer therapeutics have resulted that more precisely target the vulnerabilities revealed by genomic analysis. Emergent efforts that link the two, using machine learning approaches and circulating DNA from cancer cells, are furthering cancer diagnosis and precision medicine.

    • Elaine R. Mardis
  • The rapid progression of KRAS(G12C) inhibitors from preclinical characterization to the clinic has radically changed the perception of the KRAS oncogene as an undruggable target. Here we discuss ongoing and future possibilities for developing therapies using these inhibitors in clinical settings.

    • Rafael Rosell
    • Andrés Aguilar
    • Imane Chaib
    Clinical Outlook
  • From a first-in-class KRAS approval to the latest agonist antibody failures, 2021 was another busy year for cancer drug developers.

    • Asher Mullard
    News Feature
  • In our Focus on 2021 in Review, the Nature Cancer team and leading experts look back at the biggest developments for the cancer field over the past 12 months.